0000000000048481

AUTHOR

A. Nguyen

showing 11 related works from this author

Unexpected adverse effect of metyrapone: A case report

2018

medicine.medical_specialtyMetyraponebusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismmedicine.disease03 medical and health sciences0302 clinical medicineEndocrinologyEndocrinologyInternal medicinemedicineAdverse effectbusinessRhabdomyolysis030217 neurology & neurosurgerymedicine.drugClinical Endocrinology
researchProduct

Effet secondaire inattendu de la métyrapone : à propos d’un cas

2018

Introduction L’hypercorticisme est une pathologie rare et l’utilisation de la metyrapone est peu frequente. Le surdosage en metyrapone se traduit habituellement par des symptomes gastro-intestinaux et une insuffisance surrenalienne aigue. Observation Un diagnostic d’hypercorticisme est realise chez un homme de 28 ans. Un traitement par metyrapone 250 mg deux fois par jour a debute pour controler l’hypercorticisme. Le patient est hospitalise pour une intoxication medicamenteuse volontaire avec 100 comprimes de metyrapone. Un diagnostic d’insuffisance surrenalienne aigue est pose devant des douleurs abdominales, des vomissements, une asthenie et une hypotension. Il ne presente pas de myalgies…

EndocrinologyEndocrinology Diabetes and MetabolismGeneral MedicineAnnales d'Endocrinologie
researchProduct

Liver Fat Content in People with Pituitary Diseases: Influence of Serum IGF1 Levels

2017

AbstractNon-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity, metabolic syndrome, and type 2 diabetes. NAFLD is also seen in patients with endocrinopathies. However, the relationship between endocrine diseases and the development of NAFLD is not well known. In this study, we set out to determine whether liver fat content (LFC) was associated with IGF1 levels in people with pituitary diseases (PD). Eighty-nine patients with pituitary diseases and 74 healthy controls were included in this study. LFC was measured using MRI. Hepatic steatosis was defined as LFC>5.5%. Patients with PD were older, and had a higher BMI than healthy controls. LFC was significantly higher…

0301 basic medicineAdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismDiseaseType 2 diabetesIntra-Abdominal FatBiochemistryBody Mass Index03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyLiver fatmedicinesteatosisEndocrine systemHumansProspective StudiesInsulin-Like Growth Factor Ibusiness.industryBiochemistry (medical)Fatty liverIGF1pituitary diseasesnon-alcoholic fatty liver diseaseGeneral MedicineMiddle Agedmedicine.diseaseObesity030104 developmental biologyEndocrinologyCase-Control StudiesFemaleSteatosisMetabolic syndromebusinessBiomarkers
researchProduct

Observation of $Z$ production in proton-lead collisions at LHCb

2014

The first observation of $Z$ boson production in proton-lead collisions at a centre-of-mass energy per proton-nucleon pair of $\sqrt{s_{NN}}=5~\text{TeV}$ is presented. The data sample corresponds to an integrated luminosity of $1.6~\text{nb}^{-1}$ collected with the LHCb detector. The $Z$ candidates are reconstructed from pairs of oppositely charged muons with pseudorapidities between 2.0 and 4.5 and transverse momenta above $20~\text{GeV}/c$. The invariant dimuon mass is restricted to the range $60-120~\text{GeV}/c^2$. The $Z$ production cross-section is measured to be \begin{eqnarray*} ��_{Z\to��^+��^-}(\text{fwd})&=&13.5^{+5.4}_{-4.0}\text{(stat.)}\pm1.2\text{(syst.)}~\text{nb} …

14.70.Hp - Z bosonProtonNuclear Theory01 natural sciencesPhysics Particles & FieldsHigh Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareLuminosityHigh Energy Physics - Experiment (hep-ex)Heavy-ion collision[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Electroweak interaction; Forward physics; Heavy Ions; Heavy-ion collision; Particle and resonance productionElectroweak interactionHeavy IonsHeavy IonNuclear ExperimentQCBosonPhysics25.75.Dw - Relativistic heavy-ion collisions: Particle and resonance production; 14.70.Hp - Z bosons; 13.38.Dg - Decays of Z bosons; 12.15.-y - Electroweak interactionsPhysicsHIGH ENERGIES12.15.-y - Electroweak interactionsParticle physicsComputer Science::Computation and Language (Computational Linguistics and Natural Language and Speech Processing)13.38.Dg - Decays of Z bosons25.75.Dw - Relativistic heavy-ion collisions: Particle and resonance productionPhysical SciencesPARTON DISTRIBUTIONS; BOSON PRODUCTION; HIGH ENERGIES; NUCLEAR PDFS; DEUTERIUM; DECAYFísica nuclearProduction (computer science)14.70.Hp - Z bosonsParticle Physics - ExperimentNuclear and High Energy PhysicsParticle physicsNUCLEAR PDFS530 PhysicsDEUTERIUMFOS: Physical sciencesPhysics InstituteLHCb - Abteilung HofmannHadronsParticle and resonance production0103 physical sciencesElectroweak interaction; Forward physics; Heavy Ions; Heavy-ion collision; Particle and resonance production; Nuclear and High Energy PhysicsSDG 7 - Affordable and Clean Energy010306 general physicsForward physicLarge Hadron Collider (France and Switzerland)BOSON PRODUCTION/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energyScience & TechnologyMuon010308 nuclear & particles physicshep-exComputer Science::Information RetrievalGran Col·lisionador d'Hadrons13.38.Dg - Decays of Z bosonPARTON DISTRIBUTIONSForward physicsHigh Energy Physics::ExperimentFísica de partículesExperimentsDECAYEnergy (signal processing)JHEP
researchProduct

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Interférences des traitements par biotine avec les immunodosages : il est temps de trouver une solution à long terme !

2018

La Presse Medicale - In Press.Proof corrected by the author Available online since vendredi 22 decembre 2017

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industry030220 oncology & carcinogenesisMedicine030209 endocrinology & metabolismGeneral MedicinebusinessLa Presse Médicale
researchProduct

HIGH GRADE GLIOMAS AND DIPG

2014

OncologyCancer Researchmedicine.medical_specialtybusiness.industry03 medical and health sciencesAbstracts0302 clinical medicineText miningOncology030220 oncology & carcinogenesisInternal medicinemedicineNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Searches for violation of lepton flavour and baryon number in tau lepton decays at LHCb

2013

Searches for the lepton flavour violating decay tau(-) -> mu(-)mu(+)mu(-) and the lepton flavour and baryon number violating decays tau(-) -> (p) over bar mu(+)mu(-) and tau(-) -> p mu(-)mu(-) have been carried out using proton-proton collision data, corresponding to an integrated luminosity of 1.0 fb(-1), taken by the LHCb experiment at root s = 7 TeV. No evidence has been found for any signal, and limits have been set at 90% confidence level on the branching fractions: B(tau(-) -> mu(-)mu(+)mu(-) mu(+)mu(-)) p mu(-)mu(-)) (p) over bar mu(+)mu(-) and tau(-) -> p mu(-)mu(-) decay modes represent the first direct experimental limits on these channels.

Nuclear and High Energy PhysicsParticle physicsFlavourDecays of leptons; Global symmetries (e.g. baryon number lepton number); 13.35.-r; 11.30.Fs;FOS: Physical sciences01 natural sciencesPartícules (Física nuclear)High Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareNuclear physicslepton number)High Energy Physics - Experiment (hep-ex)Violació CP (Física nuclear)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]LHC flavour physics lepton number11.30.FsNeutrinsNeutrinos010306 general physicsParticles (Nuclear physics)Physics13.35.-rDecays of leptonsLarge Hadron Collider010308 nuclear & particles physicsGlobal symmetries (e.g. baryon number lepton number)Leptons (Física nuclear)Global symmetries (e.g.High Energy Physics::Phenomenologybaryon numberDecays of lepton3. Good healthFIS/01 - FISICA SPERIMENTALELeptons (Nuclear physics)Física nuclearHigh Energy Physics::ExperimentBaryon numberNeutrino11.30.FFIS/04 - FISICA NUCLEARE E SUBNUCLEAREParticle Physics - ExperimentLeptonCP violation (Nuclear physics)Physics Letters B
researchProduct

Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteo…

2016

The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. INTRODUCTION: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. METHODS: Baseline results are re…

Gastrointestinal DiseasesEndocrinology Diabetes and MetabolismHealth-related quality of lifeOsteoporosisFRACTURE RISKRISEDRONATE0302 clinical medicineEndocrinologyQuality of lifeBack pain030212 general & internal medicineProspective StudiesHEALTH PLANProspective cohort studyALENDRONATEOsteoporosis PostmenopausalPOPULATIONeducation.field_of_studyBone Density Conservation AgentsDiphosphonatesBISPHOSPHONATE THERAPYSettore MED/34 - Medicina Fisica E RiabilitativaTRACT SAFETYBisphosphonatesMiddle AgedEuropeDiabetes and MetabolismPOSTMENOPAUSAL WOMENPatient SatisfactionHealth ResourcesFemaleOriginal ArticlePostmenopausalmedicine.symptomBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of Life; Endocrinology Diabetes and Metabolismmedicine.medical_specialtyCanadaGastrointestinalPsychometricsPopulation030209 endocrinology & metabolismNOMedication Adherence03 medical and health sciencesInternal medicinemedicineHumanseducationBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of LifeAgedTreatment satisfactionbusiness.industryPERSISTENCEbisphosphonates gastrointestyinal osteoporosis postmenopausal treatment satisfactionBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfactionmedicine.diseaseRheumatologyCLINICAL-PRACTICEOrthopedic surgeryQuality of LifeOsteoporosisObservational studybusinessBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Endocrinology Diabetes and Metabolism
researchProduct

CO-74: Altérations majeures du sphingophospholipidome des lipoprotéines de haute densité (HDL) de patients avec syndrome métabolique et glycémie norm…

2016

Rationnel Les phospholipides et sphingolipides jouent un role primordial dans la fonctionnalite et le role anti-atherogene des HDL. Ces proprietes sont alterees chez les patients porteurs d'un syndrome metabolique avant meme l'apparition d'une hyperglycemie. Nous avons donc recherche si les HDL de ces patients presentaient des anomalies de leur sphingophospholipidome. Patients et Methodes Par chromatographie liquide couplee a la spectrometrie de masse en tandem, nous avons quantifie 80 especes moleculaires des principales classes de phospholipides et sphingolipides des HDL2 et HDL3, chez 26 patients avec un syndrome metabolique et une glycemie a jeun nor-male (14 hommes, 12 femmes, âge moye…

03 medical and health sciences0302 clinical medicineEndocrinologyEndocrinology Diabetes and MetabolismInternal MedicineDiabète030209 endocrinology & metabolismGeneral Medicine[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism030204 cardiovascular system & hematology[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism3. Good healthEndocrinologie
researchProduct

Effet secondaire inattendu de la métyrapone : à propos d’un cas

2018

[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismRhabdomyolyseMétyrapone
researchProduct